“I think it's going to be a meaningful growth driver here for our vascular business, which we've already started to see an improvement on the growth rate.”

In context

“the trial is being viewed as very easy to deliver. And seems like a great tool here to treat severe calcification. So, I've gotten, like, early data on kind of the first cases. They seem to all go very well. You know, praise from the interventionists on the deliverability of it, and I think that's always an important part given our experience in the world of stents. Deliverability is super important. So that's it seems like it's hitting the mark there. And then we also know that there's, you know, obviously, a peripheral market for this. If you think about our portfolio in our vascular business, this would complement it also very well. So I know the team's working on a peripheral program there too, and we'll provide updates on that as we progress. But, yeah, excited about the opportunity. I think it's going to be a meaningful growth driver here for our vascular business, which we've already started to see an improvement on the growth rate. And this will obviously help sustain it. Yeah. On your question on structural heart, yes, 15% growth. We've always talked about, Joanne, this being like moving away from being a single product company and MicroClip to be a full portfolio product. And the investments that we made in R&D during those years post-integration of St. Jude and really kind of building a best-in-class portfolio here, I think is going to pay off. It's paying off now, and I think it's going to pay off long-term also. Navitor is doing really well. We've talked about, you know, the opportunities that we have in TAVR, good share gains in Europe and looking forward to see this investment that we've been making in the US in terms of building our commercial presence, expanding it, looking forward to see that team be able”